Literature DB >> 14751089

Glutathione analogues in cancer treatment.

David Hamilton1, Gerald Batist.   

Abstract

Glutathione is an important intracellular antioxidant and redox potential regulator that plays a vital role in drug detoxification and elimination and in cellular protection from damage by free radicals, peroxides, and toxins. Molecular alterations reported in many of the components of the glutathione system in various tumors and cancer cell lines can lead to increased survival and enhanced chemotherapy drug resistance. Several glutathione analogues that target this system have been developed and used experimentally and clinically in an attempt to improve cancer chemotherapy. These compounds include glutathione-S-transferase inhibitors and prodrugs, glyoxalase I inhibitors, and S-nitrosoglutathione. Work with these analogues has shown promising results, although lack of tumor specificity is a potential problem. Continuing development and optimization of glutathione analogues will lead to more specific targeting of this system in cancer treatment, allowing an increased therapeutic response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751089     DOI: 10.1007/s11912-004-0023-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  60 in total

1.  Nitration of annexin II tetramer.

Authors:  William H Rowan; Peng Sun; Lin Liu
Journal:  Biochemistry       Date:  2002-01-29       Impact factor: 3.162

2.  Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.

Authors:  H Sakamoto; T Mashima; A Kizaki; S Dan; Y Hashimoto; M Naito; T Tsuruo
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

3.  Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma.

Authors:  K Emoto; Y Yamada; H Sawada; H Fujimoto; M Ueno; T Takayama; K Kamada; A Naito; S Hirao; Y Nakajima
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

Review 4.  Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor.

Authors:  P J Thornalley
Journal:  Crit Rev Oncol Hematol       Date:  1995-08       Impact factor: 6.312

5.  Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases.

Authors:  Z Yin; V N Ivanov; H Habelhah; K Tew; Z Ronai
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

6.  Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi.

Authors:  Robert Elsby; Neil R Kitteringham; Christopher E Goldring; Cerys A Lovatt; Mark Chamberlain; Colin J Henderson; C Roland Wolf; B Kevin Park
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

7.  A molecular compendium of genes expressed in multiple myeloma.

Authors:  Jaime O Claudio; Esther Masih-Khan; Hongchang Tang; Jason Gonçalves; Michael Voralia; Zhi Hua Li; Vincent Nadeem; Eva Cukerman; Ofelia Francisco-Pabalan; Choong Chin Liew; James R Woodgett; A Keith Stewart
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Nitric oxide synthase activity in human gynecological cancer.

Authors:  L L Thomsen; F G Lawton; R G Knowles; J E Beesley; V Riveros-Moreno; S Moncada
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

9.  Formation of strand breaks and interstrand cross-links in DNA by methylglyoxal.

Authors:  A Rahman; S M Hadi
Journal:  J Biochem Toxicol       Date:  1990

Review 10.  Chemical basis of inflammation-induced carcinogenesis.

Authors:  Hiroshi Ohshima; Masayuki Tatemichi; Tomohiro Sawa
Journal:  Arch Biochem Biophys       Date:  2003-09-01       Impact factor: 4.013

View more
  7 in total

1.  Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

Authors:  Sreenivasulu Chintala; Károly Tóth; Ming-Biao Yin; Arup Bhattacharya; Sylvia B Smith; M Shamsul Ola; Shousong Cao; Farukh A Durrani; Tanjima R Zinia; Rebecca Dean; Harry K Slocum; Youcef M Rustum
Journal:  Chemotherapy       Date:  2010-06-11       Impact factor: 2.544

Review 2.  NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action.

Authors:  Basil Rigas; Jennie L Williams
Journal:  Nitric Oxide       Date:  2008-04-29       Impact factor: 4.427

3.  Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.

Authors:  Anju Singh; Vikas Misra; Rajesh K Thimmulappa; Hannah Lee; Stephen Ames; Mohammad O Hoque; James G Herman; Stephen B Baylin; David Sidransky; Edward Gabrielson; Malcolm V Brock; Shyam Biswal
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

4.  Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells.

Authors:  Jessica Swanner; Jade Mims; David L Carroll; Steven A Akman; Cristina M Furdui; Suzy V Torti; Ravi N Singh
Journal:  Int J Nanomedicine       Date:  2015-06-11

5.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Authors:  Luika A Timmerman; Thomas Holton; Mariia Yuneva; Raymond J Louie; Mercè Padró; Anneleen Daemen; Min Hu; Denise A Chan; Stephen P Ethier; Laura J van 't Veer; Kornelia Polyak; Frank McCormick; Joe W Gray
Journal:  Cancer Cell       Date:  2013-10-03       Impact factor: 31.743

Review 6.  A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde.

Authors:  Jolie Kiemlian Kwee
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

7.  Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis.

Authors:  Nandini Verma; Yaron Vinik; Ashish Saroha; Nishanth Ulhas Nair; Eytan Ruppin; Gordon Mills; Thomas Karn; Vinay Dubey; Lohit Khera; Harsha Raj; Flavio Maina; Sima Lev
Journal:  Sci Adv       Date:  2020-08-21       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.